Striking changes in circadian rhythms, including the sleep-wake rhythm, characterize
many neurodegenerative processes, e.g., Alzheimer's disease (AD), Parkinson's disease,
Huntington's disease, and traumatic brain injury (TBI). Because disturbances in circadian
rhythm and sleep can precede the overt cognitive impairment, they have been postulated
as risk factors or predictors of these diseases (Musiek and Holtzman, 2016).
Circadian rhythms represent biological adaptations to dramatic and predictable daily
changes in the physical environment experienced by virtually all organisms living
on earth. By definition, circadian rhythms have an intrinsic period length of ~24
h, are endogenously generated (i.e., persist under constant environmental conditions),
are temperature compensated (i.e., the period is little affected by temperature) and
can be entrained by temporal cues (zeitgebers). Although the light-dark cycle is the
most robust zeitgeber, other factors including activity and timing of food can modify
circadian phase. Circadian rhythms govern the rhythmic expression of a large portion
of the genome (Zhang et al., 2014) and a wide range of cellular, physiological, and
behavioral processes, including the daily sleep-wake rhythm.
Sleep is regulated not only by the circadian phase but also by the time elapsed since
prior sleep (the homeostatic sleep drive), according to the two-process model of sleep
regulation (Borbély, 1982). Although these processes were initially considered to
be independent, they have since been shown to influence each other. Sleep deprivation
can alter the phase of circadian rhythms (Antle and Mistlberger, 2000) and the expression
of circadian clock genes (Franken et al., 2007). Destruction of the suprachiasmatic
nucleus (SCN), the master mammalian circadian pacemaker, not only ablates the daily
sleep-wake rhythm but also increases the total amount of sleep in squirrel monkeys
(Edgar et al., 1993) and non-REM sleep in mice (Easton et al., 2004). Thus, loss of
sleep affects the timing of circadian rhythms while circadian rhythm alterations impair
sleep, underscoring a complex relationship between these processes (Mistlberger, 2005;
Morin, 2013; Scammell et al., 2017).
Neural circuits regulating sleep and circadian rhythm output are vulnerable to brain
damage and neurodegeneration (Coogan et al., 2013; Theofilas et al., 2017). For example,
accumulation of amyloid-beta disrupts circadian rhythms and sleep (Tate et al., 1992;
Roh et al., 2012). On the other hand, disruption of circadian rhythms or sleep deleteriously
affects many physiological, behavioral, and neuronal functions (Musiek and Holtzman,
2016; Zhu et al., 2016). Current evidence suggests that the bi-directional interactions
between neurodegeneration and disruption of circadian rhythms and sleep exacerbates
neuropathology in AD and other neurological disorders (Wang and Holtzman, 2020). In
this special issue, discrete circadian rhythm alterations in these disorders and their
associations with specific neuropathological processes are described in articles by
Fifel and Videnovic and Green et al.
Sleep disruptions appear prior to the prodromal stages of AD, and include fragmentation
of the daily sleep-wake rhythm, reduced total sleep, and loss of deep sleep (i.e.,
slow wave sleep) (Tranah et al., 2011; Guarnieri et al., 2012; Lim et al., 2013; Guarnieri
and Sorbi, 2015). Two articles in this issue focus on AD-related changes in discrete
neuronal oscillations. As Mander describes, AD neuropathology is accompanied by deficits
in three types of local sleep oscillations: (1) frequency-specific frontal slow-wave
expression during non-REM sleep, (2) parietal sleep spindles expression, and (3) the
quality of electroencephalographic desynchrony in REM sleep. The association of these
specific sleep deficits with amyloid-beta and tau pathology and their potential roles
in sleep-dependent memory processes and cognitive changes in AD are discussed. The
mechanistic importance of AD-associated deficits in slow wave activity is emphasized
in the article by Lee et al., which reviews studies showing that the frequency of
slow waves affects memory consolidation, amyloid deposition, and neuronal calcium
homeostasis. Slow wave sleep is proposed as a therapeutic target for AD.
Variations in neuronal oscillatory activity also occur in patients with moderate obstructive
sleep apnea (OSA), a common breathing disorder associated with brain injury and memory
impairment. As described by Zhou et al. in this issue, dynamic changes in EEG spectral
power occur during respiratory events, including cortical hyperactivation during N2
sleep, suppression of β-band information transmission, abnormal interhemispheric effective
connectivity, and intrahemispheric “rise-to-down” fluctuations in the γ band. This
work provides insights into how OSA affects cognition and neuropsychiatric function.
To enable preclinical investigations of therapeutic strategies to ameliorate sleep
and circadian dysfunction in AD, animal models that temporally replicate these disturbances
and neurodegeneration are needed. While some AD mouse models exhibit changes in sleep
and circadian rhythms resembling those seen in AD patients, these changes are not
consistent across the models, as described by Sheehan and Musiek in this issue. This
review provides a fine-grained analysis of the expression of circadian rhythms reported
from various models and provides suggestions on how to standardize and optimize future
studies of circadian rhythms in AD mouse models. Also in this issue, Lippi et al.
describe daily activity rhythms and their responses to zinc in a novel mouse model
that exhibits amyloid and tau pathology based on a cross between the J20 (hAPP) and
P301L (Tau) lines. Sare et al. report on the TgF344-AD rat model of AD that expresses
age-dependent tau and amyloid pathology. Age-related changes in rest-activity rhythms,
cognitive performance, and hyposmia are exhibited by the TgF344-AD rats with interesting
sex-dependent effects.
Several article in this issue described basic research focused on the underlying mechanisms
linking sleep and circadian rhythm dysfunction to neurodegeneration. Sharma et al.
review this topic with a special focus on the effect of aberrant circadian rhythmicity
on E3 ligase and poly adenosine disphophate (ADP-ribose) polymerase 1 activity in
Parkinson's disease. Cassar et al. developed a knock-in Drosophila model of tauopathy
and reveal that mutant tau disrupts daily sleep rhythms independent of circadian rhythm
changes by interfering with central pacemaker neuron output connectivity. Green et
al. describe the role of sleep disruption-associated inflammation in mediating the
increased risk of AD occurring with traumatic brain injury. Todd focuses on the potential
neural pathways by which circadian rhythm disruption may cause the aggression and
agitation that AD patients exhibit during “sundowning syndrome.”
Together, the articles presented in this special issue highlight important questions
to address regarding interactions between sleep, circadian rhythms, and neurodegeneration
and describe newer models and approaches that may facilitate this work. Overall, the
work substantiates the concept that study of neural consequences of circadian and
sleep disturbances will provide insight into molecular bases of neurodegenerative
processes, while study of sleep and circadian rhythms in animal models and humans
with neurodegeneration will provide fundamental knowledge of sleep and circadian neurobiology.
These efforts will meet with the greatest success when experts in all three fields
collaborate.
Author Contributions
MD wrote this editorial. SV and PZ provided revisions.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily
represent those of their affiliated organizations, or those of the publisher, the
editors and the reviewers. Any product that may be evaluated in this article, or claim
that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.